AST - DOAJ

Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120

In chronic kidney disease patients' organs, inflammatory toxins, such as indoxyl sulfate and p-cresol, or p-cresyl sulfate, are largely present in renal kidney disease patients's kidneys. Oral sorbent AST-120 reduces serum levels of uremic toxins in CKD patients by adsorbing the precursors of IS and PCS that are metabolized by amino acid metabolism in the intestine. Though large-scale studies showed no apparent benefits from adding AST-120 to the standard therapy for CKD patients, subsequent sporadic experiments may confirm the drug's use. This article summarizes the mechanisms of uremic toxins, IS, and PCS, and discusses the multiple effects of AST-120 in CKD patients.

Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques

Patients with persistent kidney disease have elevated circulating uremic toxins, contributing to a variety of signs and organ dysfunction. Both Indoxyl sulfate and p-cresyl sulfate are two common uremic chemicals with varying adverse effects. Following AST-120 treatment resulted in the improvement of renal failure-associated muscle atrophy, which in skeletal muscle atrophy, which reduced accumulation. We conclude that uremic toxins can accumulate in various organs and that AST-120 can be helpful in treating or preventing organ dysfunction in CKD, notably by reducing tissue uremic toxins accumulation.

The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer

Aminotransaminases, including aspartate aminotransaminase and alanine aminotransaminase, are important in cancer cell metabolism and have been associated with prognosis in several forms of cancer. Term of the present investigation The aim of the present study was to determine the sigmatic value of the pre-treatment AST/ALT ratio in a large European cohort of patients with oral and oropharyngeal squamous cell carcinoma. A retrospective review of 515 patients treated for OOSCC at a Tertiary academic center from 2000-2017 was retrospectively collected. The AST/ALT ratio with CSS and OS was shown to have a strong correlation with Univariate results. For the AST/ALT ratio, the appropriate cut-off point was 1. 44, respectively, based on receiver operating characteristics curve results. The AST/ALT ratio is a prognostic indicator for survival in OOSCC patients, and it could be a factor determining better risk stratification and improved oncological therapy decisions.

An AST-ELM Method for Eliminating the Influence of Charging Phenomenon on ECT

Perpetivity tomography (Permission tomography) is a promising imaging method for permittivity distributions in multiphase flow. An advanced extreme learning machine method combined with adaptive soft-thresholding is introduced and tested for image reconstruction in order to reduce the effect of charging phenomenon on ECT measurement. The image reconstruction accuracy by the new AST-ELM technique has greatly improved than that achieved by the conventional methods under the condition of a charging object.

A Metabolomic Approach to Clarifying the Effect of AST-120 on 5/6 Nephrectomized Rats by Capillary Electrophoresis with Mass Spectrometry (CE-MS)

AST-120, the oral adsorbent, is made of spherical carbon particles and has an adsorption capability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease. We investigated the plasma concentrations of 146 compounds in CKD model rats, with or without four weeks of AST-120 treatment, in order to determine the effects of AST-120 in vivo. According to the sham-operated group, the plasma concentrations of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, etc; were noticeably down in the CKD model, compared to the sham-operated group, and imidazole-4-acetate were significantly reduced by AST-120 treatment. Also, these ten compounds could be included as uremic compounds that show the results of AST-120 therapy. This research provides valuable insight not only for identifying the AST-120-120's characteristics but also for determining changes in the metabolic profile by AST-120 therapy in the clinical setting.

Association of serum brain-derived neurotrophic factor with hepatic enzymes, AST/ALT ratio, and FIB-4 index in middle-aged and older women.

Evidence from published studies shows that liver function plays a key role in brain health. A key brain regulator of brain function is a brain-derived neurotrophic factor. Hence, we hypothesized that blood BDNF levels are related to liver function and fibrosis. After adjustment for age, we found that serum BDNF showed a significant positive correlation with ALT and u03b3-glutamyltranse production, negative correlation with the FIB-4 index, and a pattern of negative correlation with the AST/ALT ratio. These results show links between serum BDNF levels and liver enzymes and hepatic fibrosis-related indices, which may be responsible for liver-brain interactions.

Association of serum brain-derived neurotrophic factor with hepatic enzymes, AST/ALT ratio, and FIB-4 index in middle-aged and older women

Evidence shows that liver function plays a crucial role in brain health. Therefore, we hypothesized that blood BDNF levels were related to liver function and fibrosis. After age adjustment for age, we discovered that serum BDNF showed a significant positive correlation with ALT and u03b3-glutamyltranspeptide production, as negative correlation with the FIB-4 index, and a decreasing trend in negative correlation with the AST/ALT ratio. These results show a correlation between serum BDNF and liver enzymes and hepatic fibrosis-related indices, which may be responsible for liver-brain interactions.

Study of B c + → J / ψ D s + $${\mathrm{B}}_{\mathrm{c}}^{+}\to \mathrm{J}/\psi {\mathrm{D}}_{\mathrm{s}}^{+}$$ and B c + → J / ψ D s ∗ + $${\mathrm{B}}_{\mathrm{c}}^{+}\to \mathrm{J}/\psi {\mathrm{D}}_{\mathrm{s}}^{\ast +}$$ decays in pp collisions at s $$\sqrt{\mathrm{s}}$$ = 13 TeV with the ATLAS detector

0. 70 % 0. 11 u00b1 0. 11 according to the B c+ / u0393 D / u2393 / u0393 D s u2217+1 B_c^+2̆192J/0̆3c8D_s^2̆217+ decay, the transverse polarization fraction, u2393 / u00b1 / u0393, is reported to be 0. 70 / 0. 11 / 0. 11. These results supersede those obtained in the earlier ATLAS study of the same decays with 2̆21a(s) = 7 and 8 TeV pp collision data.